Homology Medicines
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Homology Medicines's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 64% to $1,156,000. Profit margin reached -9772%. Total operating expenses were $92,680,000.

Profit Margin

Homology Medicines, Inc. (NASDAQ:FIXX): Profit margin
2016 0 -8.04M
2017 0 -29.99M
2018 3.68M -57.21M -1553.07%
2019 1.66M -97.88M -5875.69%
2020 2.70M -127.12M -4704.85%
2021 33.97M -95.57M -281.35%
2022 3.20M 483K 15.06%
2023 1.15M -112.96M -9771.71%

FIXX Income Statement (2016 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016
Revenue
Revenue
1.15M3.20M33.97M2.70M1.66M3.68M00
Cost of revenue
578K2.59M9.54M100.39M89.39M000
Gross profit
578K609K24.42M-97.69M-87.73M3.68M00
Operating exp.
Research and development
62.00M98.35M93.08M100.39M89.39M47.94M21.37M5.69M
Selling and marketing
-578K0000000
Total operating expenses
92.68M136.48M129.92M132.96M111.60M65.24M29.65M10.00M
Operating income
-92.10M-133.28M-95.94M-130.26M-109.94M-61.56M-29.65M-10.00M
Other income (expenses), net
14.34M134.47M185K1.56M6.02M4.34M-333.36K1.92M
Income before tax
-87.08M1.19M-95.76M-128.69M-103.91M-57.21M-29.99M-8.04M
Income tax expense
25.88M715K-185K-1.56M-6.02M4.34M-542.63K-24.20K
Net income
-112.96M483K-95.57M-127.12M-97.88M-57.21M-29.99M-8.04M
Earnings per share
Basic EPS
-351.571.51-311.2-498.41-418.35-360.7-159.96-77.86
Diluted EPS
-351.571.51-311.2-498.41-418.35-360.7-159.96-77.86
Data sourceData sourceData sourceData sourceData sourceData source